Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Jul
23
Today In Oncology
FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC
AI-Derived Bone Marrow Architecture Score Improves Disease Assessment in Myelodysplastic Neoplasms
Multiple Myeloma Studies Highlight Advances Across the Field
Early Research Examines Daraxonrasib in NRAS-Mutant Melanoma
Can Consolidative Thoracic Radiotherapy Improve Outcomes During Immunotherapy Maintenance in Extensive-Stage SCLC?
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo